Abstract：【Objective】To explore the association between aminoacyl-tRNA synthetases and survival probability of lung adenocarcinoma via integrated analysis. 【Methods】We first obtained the gene expression data and clinical records of lung adenocarcinoma from the TCGA platform. Then we used GSEA analysis to explore the overall expression status of the aminoacyl-tRNA synthetase family in lung adenocarcinoma. Finally, we analyzed the relationship of the metabolic enzymes with total survival and progression-free survival of lung adenocarcinoma. 【Results】We found that the aminoacyl-tRNA synthetase family was highly expressed in lung adenocarcinoma. Survival analysis revealed that seven out of these enzymes were associated with overall survival of lung adenocarcinoma, and four enzymes were associated with progression-free survival. Patients with high expression of these enzymes showed worse prognosis. 【Conclusion】Aminoacyl -tRNA synthetases are highly expressed in lung adenocarcinoma and are closely related to survival probability. This provides a reference for understanding the metabolic characteristics and prevention methods of lung adenocarcinoma.
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics[J].CA Cancer J Clin, 2019[Epub ahead of print]. [2] Torre LA, Bray F, Siegel RL,et al. Global cancer statistics[J].CA Cancer J Clin,2015, 65(2): 87-108. [3] Toschi L, Rossi S, Finocchiaro G, et al. Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come[J].Ecancermedicalscience,2017, 11: 787. [4] Reck M, Rabe KF. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer [J].N Engl J Med,2017, 377(9): 849-861. [5] Park SJ, More S, Murtuza A, et al. New Targets in Non-Small Cell Lung Cancer [J].Hematol Oncol Clin North Am,2017, 31: 113-129. [6] Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments[J].Lancet,2017, 389(10066): 299-311. [7] Remon J, Hendriks LE, Cabrera C, et al. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change[J]?Cancer Treat Rev,2018, 71: 47-58. [8] Cyriac G, Gandhi L. Emerging biomarkers for immune checkpoint inhibition in lung cancer[J].Semin Cancer Biol,2018,52(Pt 2):269-277. [9] Suresh K, Naidoo J, Lin CT, et al. Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities[J].Chest,2018,154(6):1416-1423. [10] Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology[J].Cell,2017, 168(4): 657-669. [11] Vernieri C, Casola S, Foiani M, et al. Targeting cancer metabolism:dietary and pharmacologic interventions[J].Cancer Discov,2016, 6(12): 1315-1333. [12] Sullivan LB, Gui DY, Heiden MGV. Altered metabolite levels in cancer: implications for tumour biology and cancer therapy[J].Nat Rev Cancer,2016,16:680-693. [13] Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism[J].Cell Metab,2016, 23(1): 27-47. [14] Yakobov N.Cytosolic aminoacyl-tRNA synthetases: Unanticipated relocations for unexpected functions[J].Biochim Biophys Acta,2018, 1861(4): 387-400. [15] Guo M, Yang XL, Schimmel P. New functions of aminoacyl-tRNA synthetases beyond translation[J].Nat Rev Mol Cell Biol,2010, 11(9): 668-674. [16] Park SG, Schimmel P, Kim S. Aminoacyl tRNA synthetases and their connections to disease[J].Proc Natl Acad Sci USA,2008, 105(32): 11043-11049. [17] Kim D.Association of aminoacyl-tRNA synthetases with cancer[J].Top Curr Chem,2014, 344: 207-245. [18] Kim S, You S, Hwang D. Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping[J].Nat Rev Cancer,2011, 11(10): 708-718.
2019, Vol. 36 
